drugset / Trial / NCT01029405

Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

NCT01029405

Phase 2 Completed 145 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment B, 2.0% and 0.5%, compared to Ointment Vehicle B, applied once or twice daily for 12 weeks, in the treatment of plaque type psoriasis

Timeline

Start
2009-11
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Crisaborole Small molecule 0.5 %
Comparator Crisaborole Small molecule 2 %

Indications